Evidence map›Paper›PMID 40877334›Full record

ReviewNature reviews. Disease primers2025

Diabetic retinal disease.

Sobha Sivaprasad, Tien Yin Wong, Thomas W Gardner, Jennifer K Sun, Neil M Bressler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sobha SivaprasadNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. sobha.sivaprasad@nhs.net.ORCID http://orcid.org/0000-0001-8952-0659
Tien Yin WongBeijing Visual Science and Translational Eye Research Institute, Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Beijing, China.ORCID http://orcid.org/0000-0002-8448-1264
Thomas W GardnerDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Jennifer K SunDepartment of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Neil M BresslerWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy is a complication of diabetes mellitus that is clinically characterized by changes in retinal microvasculature. Diabetic retinopathy is now better defined as diabetic retinal disease (DRD), as diabetes mellitus affects not only the retinal microvasculature but the whole retina, including neurons and glia. A global concerted effort to study preclinical and clinical signs of DRD and their association with visual acuity and patient-reported vision-related quality of life, and the integration of these features with systemic health and biochemical milieu in people with diabetes mellitus is underway. The Diabetic Retinopathy Clinical Research Retina Network trials and other researchers have provided substantial robust evidence on the current management of vision-threatening diabetic retinopathy that includes proliferative diabetic retinopathy and diabetic macular oedema. Progress is also being made to develop, evaluate and implement cost-effective strategies for personalized screening, treatment and monitoring, incorporating artificial intelligence as clinical decision support tools, where appropriate. In addition, novel therapies and modes of delivery are being evaluated to increase durability of interventions and improve affordability to improve vision-related quality of life and reduce the global burden of blindness owing to DRD.

Indexed as

Diabetic RetinopathyHumansQuality of LifeRetinaVisual Acuity

Identifiers

PMID40877334

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.